Strand Life Sciences Launches StrandOmics Portal to Advance Rare Disease Diagnosis
Alongside the launch of the StrandOmics Portal, the company has announced a special initiative to offer genetic testing at reduced costs for individuals from economically disadvantaged backgrounds.
Marking Rare Disease Day, Strand Life Sciences, a subsidiary of Reliance Industries and a leading genomics research company, has launched the StrandOmics Portal, a cutting-edge digital platform designed to assist doctors in diagnosing rare diseases more efficiently and accurately.
The new portal provides clinicians with rapid and detailed genetic insights, offering a comprehensive assessment of genetic variants to facilitate faster and more precise diagnoses.
This innovation aims to shorten the often-prolonged diagnostic journeys that many rare disease patients experience.
Making Genetic Testing More Accessible
Alongside the launch of the StrandOmics Portal, the company has announced a special initiative to offer genetic testing at reduced costs for individuals from economically disadvantaged backgrounds.
This initiative seeks to ensure that essential diagnostic services for rare diseases are more widely accessible, helping underserved communities benefit from advanced genetic testing.
The StrandOmics Portal is designed to enhance clinical decision-making by offering multiple key benefits, including faster genetic insights, an independent review of a broader range of genetic variants, and enhanced collaboration among specialists to improve prenatal diagnosis and rare disease management.
Speaking about the initiative, Dr. Ramesh Hariharan, CEO and Co-Founder of Strand Life Sciences, said, “We are dedicated to improving genetic diagnostics and ensuring accessibility for all. With the launch of the StrandOmics Portal, we aim to empower doctors with better tools to combat rare diseases. We will continue to innovate and invest in advancing genetic testing technologies.”
Strand Life Sciences is a pioneer in genomic diagnostics, with expertise spanning oncology, rare diseases, women’s health, and infectious diseases.
The company combines bioinformatics, cutting-edge laboratory research, and an extensive hospital partner network to drive advancements in personalized medicine.
Stay tuned for more such updates on Digital Health News.
